Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 26, 2021

Primary Completion Date

May 4, 2022

Study Completion Date

May 4, 2022

Conditions
Solid and Hematological Malignancies
Interventions
DRUG

Capivasertib

Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.

DRUG

Rabeprazole

Participants will receive twice daily oral doses of rabeprazole for 3 days (Days -3 to -1) and a single dose on the morning of Day 1 for Treatment C.

Trial Locations (1)

14050

Research Site, Berlin

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY